Proven track record as a biotech innovator. Developed a key technology, restriction enzyme free cloning underlaying the formation of Modular Genetics, Inc. (patent US 20050191623A1),
Joined Symphogen A/S in 2000 as it started its due diligence at start-up. Developed the mammalian expression platform (patent WO/2004/061104) as well had the key idea for the development of the symphogen cognate pair antibody cloning technology as published in 2006(doi:10.1016/j.jmb.2006.02.040).
In his tenure at Symphogen, Vincent helped to make human polyclonal antibodies against tetanus, flu, RhesusD and vaccinia.
In addition to his work at Symphogen, Vincent has served as a long time consultant to the Harvard Physics department and is a Fellow at Harvard University.
vwc[@]excelimmune.com
tel: +1-617-497-4303, x14
fax: +1-617-812-0098